Novo Nordisk President and CEO Mike Doustdar joined FOX Business\u2019 Cheryl Casone on “Mornings with Maria<\/a>” to discuss the adoption of GLP-1 drugs, their potential economic impact and the company\u2019s outlook for medicines, including Wegovy.<\/p>\n Mike Doustdar, chief executive officer of Novo Nordisk, speaking during an interview. (Michael Nagle\/Bloomberg \/ Getty Images)<\/p>\n “We are clearly at early innings,” Doustdar said, pointing to the large population living with obesity and relatively limited use of GLP-1 medications. He said more than 100 million people in the U.S. are suffering from obesity<\/a>, while “somewhere around 10, 15% in a good day” have used a GLP-1.<\/p>\n TOM BRADY TEAMS WITH DIGITAL HEALTH FIRM EMED TO EXPAND GLP-1 WEIGHT LOSS MEDICATION ACCESS<\/a><\/p>\n “There is a long runway still,” he said.<\/p>\n Beyond weight loss, Doustdar said wider use of the drugs could eventually help Americans save on healthcare costs<\/a> while bringing broader economic benefits.<\/p>\n Stuart Varney and Taylor Riggs discuss Eli Lilly’s massive revenue surge driven by GLP-1 obesity drugs Mounjaro and Zepbound, and how the diet craze is negatively impacting food brands like Kraft Heinz.<\/p>\n “I do think as we get there, not only you see the health benefits of these drugs, you also see the economical benefit of these drugs<\/a>,” he said.<\/p>\n Doustdar pointed to medication use<\/a> as one area where a healthier, smaller population could reduce consumption. He used insulin, another product sold by Novo Nordisk, as an example of how dosage can vary with body size.<\/p>\n NOVO NORDISK SUES ELI LILLY OVER CLAIMS IN WEIGHT-LOSS DRUG ADS<\/a><\/p>\n “I sell insulin, and I know that a person who is larger does more insulin dose than someone who’s smaller,” he said.<\/p>\n A panel examines the expansion of GLP-1 medications beyond weight loss, exploring new medical uses, potential side effects and what the next wave of these blockbuster drugs could mean for patients on ‘Barron’s Roundtable.’<\/p>\n He also pointed to the potential value of healthier people returning to work<\/a> and becoming more productive, arguing that the benefits could extend beyond the number on a scale.<\/p>\n “Then, of course, comes on top of that, the economical value that comes from people getting back to work healthier,” Doustdar said. “People are more productive.”<\/p>\n![\"Novo](\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/08\/novo-nordisk-ceo-mike-doustdar.png\")
<\/p>\n